Professional Documents
Culture Documents
Tota 7700.00
Paid Amount 0.00
Due Amount 7700.00
RS SEVEN THOUSAND SEVEN HUNDRED ONLY. ]
Prepered By. USERÍ Signatory
Rernarks- SON
emell sundiagnostics.jrt@gmail.com
3 t ATAT (AIT AT (ST AINDLABS
DIAGNOSTIC CENTRE
An initdative of HIL lifecere lid, AGovi. of India Enterprise
CONFIDENTIAL
25Z00190021252 UID 35211984
ID No. Mr. Jogen Ch. Das Age/Sex 78 Year/ Male
Name
Reg.Date/Time :28-06-2021 16:38:09
Reff.by :Dr.B.BDispensary
Jorhat Urban Centre Coll.Date/Time :28-06-2021 16:44:36
Farility Name
: Departments of Medicine Client Name NHM
eartment Name Print Date/Time: 29-06-2021 09:43:22
ID Type OPD
ID Number 3778
BIOCHEMISTRY
Renal Function Function Test (RFT)
luvestigation Result Unit Bio.Ref Interval
Blood Urea 27 mg/dl 15-40
Sampie Type: Serum
Methoa: UR*CASE GLDH
-End Of Report
CONFIDENTIAL
25200190021252 UID: : 35211984
D No. :78Year/ Male
Näne
Mr. Jogen Ch. Das Age/Sex
Reg.DateTime :28-06-2021 16:38:09
Dr.B.B Dispensary
.by 28-06-2021 16:44:36
F: ty Name Jorhat Urban Centre Coll.Date/Time
ofMedicine Client Name : NHM
Lprtnent Name: Departments Print Date/Time: 29-06-2021 09:43:23
OPD
D Type ID Number : 3778
BIOCHEMISTRY
Investigation Result Unit Bio Ref.Interyal
Sodium 139 mmol/L 135-145
CONEIDENTIAL
BZ00T9002T252 UID 35211984
D No. Age/Sex 78 Year/ Male
Mr Jogen Ch. Das Reg.Date/Time :28-06-2021 16:38:09
Relf.by Dr.B.B Dispensary Coll.Date/Time : 28-06-2021 16:44:36
Facility Name Jorhat Urban Centre
Departments of Medicine Client Name NHM
Department Name
Print Date/Time: 29-06-2021 09:43:23
D Type OPD
ID Number :3778
BIOCHEMISTRY
Liver Function Test (LFT)
REPORT
REPORT ON; CBC Vith Differenial/ Platclet
ESTNAME RESULT METHOD UNITS
TOTAL WBC COUNT REFERENCE RANGE
8,050 Cellcounter & microscopy cumm 4000-11000
RBC COUNT
5.16 Cellcounter million/cumm 4.2-6.6 (M)
3.6-5.6 (F)
HAEMOGLOBIN 14.0
Cyanmethaemoglobin gm/dl 13-18gm/dl (M)
& Cellcounter
11-16gm/dl (F)
HCT (PCV) 44.0 Cellcounter % 40-54 (M)
35-42 (F)
MCV 85.3 Cellcounter 76-96
MCH 27.2 Cellcounter 27-32
MCHC 31.8 Cellcounter gdl 31-35
RDW 12.3 Cellcounter % 11.0 16.0
PCT 0.87 Cellcounter mL/L 1.08-2.82
PLATELET COUNT
158,000 Cellcounter & microscopy cumm
140,000-440,000
MPV 15.1
Cellcounter 7.0-11.0
ESR
07 Westergren mm AEFHH 0-20 (M)
0-30 (F)
DIFFERENTIAL COUNTI
NEUTROPHILS 61 Microscopy 40-75
LYMPHOCYTES 31
Microscopy 20-45
MONOCYTES 06 Microscopy 2-8
EOSINOPHILS 02
Microscopy 1-6
NOTE Test Performed
by five part fully automatie llematology Analyzer.(BC- 5000, Mindray)
sUGGESTED: CORRELATE WITIH CLINICAL CONDITION
REPORT
REPORT ON:
TEST NAMB RESULT METHOD UNITS REFERENCE RANGE
GAMMA GT 40 Carboxy Substrate UL 10.0 50.0 (M)
7.00-35.0 (F)
REPORT ON:
Primary Sample : Serum
REPORTON:
TEST NAME RESULT METHOD UNITS
PRO Calcitonin 3.09 Chemiluminescence ng/mL
immunoassay (CLIA)
PCT Reference Range <0.5 ng/mL >0.5 ng/mL 2.0 ng/mL >10.0 ng/mL
Interpretation of Systemic Bacterial Infection UNLIKELY POSSIBLE LIKELY VERY LIKELY
Progression to Severe sepsis And/or septic shock LOW RISK MODERATE RISK HIGH RISK VERY RISK
N.B.: It is recommended to retest PCT within 6-24hours if any concentration is <2.0 ng/mL is obtained.
REPORT
Clinical Significance of D-Dimer: The formation of D-Dimer requires three hemostatic stages: formation of clot
coagulation), Factor XIlla croslinking, and clotbreakdown of fibrin (fibrinolysis). Several studies have shown a correlation of
increased D-Dimer levels with clinical conditions that relate to the formation of fibrin, mirroring an in vivo lysis of fomed cross
-liked fibrin. This conditions include deep venous thrombosis (DVT), disseminated intravascular coagulation (DIC), pulmonary
embolism (PE), post operative states, malignancy, trauma, and pre-eclampsia. Signs and symptoms of (DVT are non-specific and
present in a Myriad of non-thrombotic disorders; hence, timely accurate, and fast D-Dimer assay could provide significant utility for
managing and monitoring patients with suspected DVT. Pulmonary embolism may result from deep vein thrombosis; hence stressing
an essential need of early diagnosis and treatment of DVT.
1) D- Dimer half-life is approximately six hours in circulation of individuals with normal renal function.
Patients with stabilized clots and not undergoing active fibrin deposition and plasmin activation may not
give detectable D-Dimer elevations anti-coagulant therapy.
2) The largerthe clot size, higherthe expected levels ofcirculating D-Dimer, conversely, the amount of D-Dimer release fom
very small clots may be diluted by the circulation and may not give a detectable increase.
3) Fibrinolysis isa highly regulated process and in delicate dynamic balance. In case of hereditary, acquired deficiency and
dysfunction of Fibrinogen, the rate offibrinolysis will be altered there by not givin detectable D-Dimer level.
4) False positive may be seen with high levels rheumatoid factor, bilirubin, lipemic serum and hemolysed blood.
REPORT
REPORTON
TEST NAME
METHOD RESULTI UNITS REFERENCE RANGE
TSH E.C.L.I.A 9.76 uIU/ml 0.270-4.20 uTU/ml
Below mentioned are the guidelines for pregnancy related reference ranges
for TSH
Trimester NORMAL TSH LEVEL
1 Trimester 0.1-2.5 lU/ml
2nd Trimester 0.2-3.0 uU/ml
3 Trimester 0.3-3.0 uU/ml
REPORT
ANTI SARS COV-2 ANTIBODY
SAMPLE: SERUM
Method ECLIA
Covid Antibody Total- This test is a screening test to understand your immunity status against Covid infection. Positive result
indicates you had an exposure in past. Negative result indicates you have not got exposed. The test is not meant or used for
diagnosis of active COVID infection.
The kit used is approved byICMR. It uses recombinant protein representing the nucleocapsid (N) antigen for the determination of
antibodies against SARS-COV-2.
BothIgM & IgG have been detected as early as day 5 after symptom onset. Median seroconversion has been observed at day 10-13
for IgM &day 12-14 for lgG, while maximum levels have been reported at week 2-3 for IgM and week 3-6 for Ig & week 2 for
total antibody wherever IgM seemsto vanish around week 6- 7 high IgG seropositivity is seen at that time. This assay cts IgM,
IgA or IgG antibodies if they are high affinity antibodies, which appear in the late or convalescent phase of infection.
Kit used
Elecsys Anti- SARS Cov 2, Manufactured by Roche Diagnostics.
N.B:All reference ranges are age and sex matched. Reference limits mentioned herein are in accordance with the literature
provided along with the kit.